Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
#2936 Mutational Landscape of 109 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms G3
Introduction: Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) G3 are rare with a poor outcome. Molecular data for GEP NEN G3 is limited and the 2019 WHO classification is based on morphology and proliferation rate.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Elvebakken H
Authors: Venizelos A, Elvebakken H, Perren A, Hjortland G, Sundlöv A,
Keywords: molecular genetics, neuroendocrine carcinoma, neuroendocrine tumors, gastroenteropancreatic, mutations,
#2834 Tumor-Promoting Effects of the Transcriptional Regulator CUX1 in PanNET
Introduction: Previously, we identified CUX1 as mediator of metastatic behaviour and poor differentiation in human insulinomas. CUX1 mediated tumor-promoting functions via enhancing proliferation, resistance to apoptosis and angiogenesis in-vitro and in-vivo.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Weißbach J
Authors: Weißbach J, Schmitz R, Haybäck J, Perren A, Blank A,
Keywords: CUX1, RIP1Tag2, DAPK1, Apoptosis, Tumor Progression,
Introduction: Hypoxia in human tumours is associated with a poor prognosis and is characterized by the stabilization of HIF1α, upregulation of VEGF, and a high microvessel density (MVD). Interestingly, although pancreatic neuroendocrine tumours (pNETS) showing hypoxia signalling also have a poor prognosis, they paradoxically display a low MVD. We hypothesized that this paradoxon might be explained by alternative splicing of VEGF.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Schmitt A
Authors: Marinoni I, Naim S, Centeno I, Perren A, Schmitt A,
#1780 PD-L1 Is Expressed in a Subset of Pancreatic Neuroendocrine Tumors (pNET)
Introduction: Programmed death 1 (PD-1) is an immune inhibitory receptor expressed on several immune cells, interacting with two ligands, PD-L1 and PD-L2. The former is expressed in many human cancers and is used as a selection criterion for indication of checkpoint inhibitor therapies. PD-L1 is also a potential target for checkpoint inhibitors in pNET therapy, however no data on prevalence of PD-L1 expression and potential associations to clinico-pathologic features is available.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Saganas C
Authors: Saganas C, Blank A, Franzelli M, Marinoni I, Perren A,
Keywords: neuroendocrine, tumors,
Introduction: ATRX and DAXX mutations associated with alternative lengthening of telomeres ( ALT) phenotype have been shown as one of the major altered pathways in pancreatic neuroendocrine tumors (PanNET).
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author:
Authors: Neumayer B, Normand L, Hoffmeister M, Friemel J, Perren A,
Keywords: DAXX, ATRX, Alternative lengthening of telomeres, neuroendocrine tumor, Insulinoma,